Healthcare organizations are charging full-speed into AI-enabled medication management, but patients aren't coming along for the ride. A nationwide survey by Wolters Kluwer Health has exposed a striking disconnect: while 99% of healthcare organizations report advancing toward AI-enabled medication workflows, only 27% of consumers strongly trust automated systems to flag drug interactions without direct clinician involvement.

The research, conducted by CITE Research in August 2024 across 1,016 healthcare consumers and 117 senior leaders from pharmacy benefit managers, payer drug management teams, retail pharmacies, and digital health technology companies, reveals fundamental tensions that could derail the industry's AI transformation.

The Verification Paradox: Patients Don't Trust What They Can't See

The trust deficit manifests in concrete defensive behaviors. Sixty-eight percent of consumers say they would independently verify medication details, pill counts, or dosages always or most of the time if generated through AI-assisted processes—a verification rate that threatens to undermine the efficiency gains AI promises.

When it comes to discussing complex medication issues like adverse events and side effects, patients overwhelmingly prefer human interaction. Fifty-nine percent want to interact exclusively with healthcare professionals for these conversations, while 33% prefer hybrid models. Only 8% are comfortable with AI-only interactions.

The channel trust disparity is equally stark. While 86% of consumers feel comfortable with traditional retail pharmacies and 78% trust health plan benefit programs, only 35% are comfortable with fully automated kiosks or self-service dispensary lockers.

The Interoperability Crisis Behind the Trust Gap

Healthcare executives recognize that trust requires more than technological capability—it demands transparency and governance. Ninety-one percent rate human reviewability as very or extremely important, and approximately 90% demand source transparency, reproducible logic, and strict governance controls.

Yet implementation barriers persist. Fifty-three percent of healthcare professionals identify inadequate interoperability with external ecosystem partners as a barrier to AI implementation, rising to 59% among digital health technology companies specifically.

The fragmentation problem is already creating real-world friction. Fifty-seven percent of consumers have experienced medication information or care coordination breakdowns, and 51% have faced prior authorization friction. Perhaps most troubling: 46% of patients who actively use digital health tools report higher coordination friction than non-users—suggesting that current multi-platform strategies are creating fragmentation rather than integration.

Building Trust Through Curated Intelligence

Healthcare leaders understand that AI acceleration requires a foundation of verified clinical knowledge. Ninety-eight percent expect their organizational dependence on curated, continuously maintained medication intelligence to increase with automation.

When asked what would build confidence in AI medication workflows, 36% of leaders cited greater confidence in underlying therapeutic and medication intelligence as most critical, while 23% prioritized stronger governance and reviewability. Notably, only 9% prioritized access to larger volumes of raw medication data—suggesting quality trumps quantity.

Wolters Kluwer's response to these challenges, Medi-Span Expert AI, deploys Model Context Protocol (MCP)-enabled connectivity to link large language models to the Medi-Span Generic Product Identifier ontology, Price Rx databases, and expert-curated clinical screening algorithms. The approach represents a broader industry shift toward grounding AI systems in verified clinical realities rather than unstructured data pools.

As healthcare explores new frontiers—including legislative sandboxes and pharmacy board trials in Utah examining autonomous prescribing—the 72-percentage-point gap between enterprise adoption and consumer trust represents more than a communication challenge. It signals that the path to effective AI integration requires transparent governance frameworks, standardized grounding protocols, and hybrid human-AI models that preserve the clinical oversight patients demand while delivering the efficiency healthcare organizations need.

Sources

  1. Wolters Kluwer Survey Exposes the Chasm Between Enterprise AI Acceleration and Consumer Drug Safety Trust — HIT Consultant